<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Itonis, Inc.</title> <link>https://www.globenewswire.com/rssfeed/organization/NU1lLzsR6ee0jHZ3hi0uBw==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2018, Itonis, Inc.</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Wed, 26 Sep 2018 18:11:57 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/09/26/1576777/26289/en/Itonis-Inc-announces-Emesyl-Plus-homeopathic-nasal-spray-containing-Premium-Hemp-Oil.html</guid> <link>https://www.globenewswire.com/news-release/2018/09/26/1576777/26289/en/Itonis-Inc-announces-Emesyl-Plus-homeopathic-nasal-spray-containing-Premium-Hemp-Oil.html</link> <category domain="https://www.globenewswire.com/rss/stock">OTC Markets:ITNS</category> <category domain="https://www.globenewswire.com/rss/ISIN">US4657331033</category> <title>Itonis, Inc. announces “Emesyl® Plus” homeopathic nasal spray containing Premium Hemp Oil</title> <description><![CDATA[<p align="left">LAGUNA HILLS, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Itonis, Inc. (OTC PINKSHEETS: ITNS)<br></p>]]></description> <pubDate>Wed, 26 Sep 2018 18:11 GMT</pubDate> <dc:identifier>1576777</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Wed, 26 Sep 2018 18:11 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>Emesyl</dc:keyword> <dc:keyword>homeopathic</dc:keyword> <dc:keyword>ITNS</dc:keyword> <dc:keyword>pharmaceutical</dc:keyword> <dc:keyword>nausea relief</dc:keyword> <dc:keyword>Cannabis Hemp Oil</dc:keyword> <dc:keyword>Emesyl Plus</dc:keyword> <dc:keyword>Itonis</dc:keyword> <dc:keyword>nasal spray</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/01/02/1277235/26289/en/Itonis-Inc-Provides-Update-for-its-Emesyl-Anti-nausea-Product-Sales.html</guid> <link>https://www.globenewswire.com/news-release/2018/01/02/1277235/26289/en/Itonis-Inc-Provides-Update-for-its-Emesyl-Anti-nausea-Product-Sales.html</link> <category domain="https://www.globenewswire.com/rss/stock">OTC Markets:ITNS</category> <category domain="https://www.globenewswire.com/rss/ISIN">US4657331033</category> <title>Itonis, Inc. Provides Update for its Emesyl® Anti-nausea Product Sales</title> <description><![CDATA[<p>Laguna Hills, CA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- <strong></strong></p>]]></description> <pubDate>Tue, 02 Jan 2018 19:48 GMT</pubDate> <dc:identifier>1277235</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Tue, 02 Jan 2018 19:48 GMT</dc:modified> <dc:subject>Press releases</dc:subject> <dc:keyword>homeopathic</dc:keyword> <dc:keyword>Emesyl</dc:keyword> <dc:keyword>pharmaceutical</dc:keyword> <dc:keyword>nausea relief</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/27/1045204/0/en/Itonis-Inc-Announces-Its-Emesyl-Anti-Nausea-Product-is-Again-Available-for-Purchase-via-Amazon-com.html</guid> <link>https://www.globenewswire.com/news-release/2016/09/27/1045204/0/en/Itonis-Inc-Announces-Its-Emesyl-Anti-Nausea-Product-is-Again-Available-for-Purchase-via-Amazon-com.html</link> <title>Itonis, Inc. Announces Its Emesyl Anti-Nausea Product is Again Available for Purchase via Amazon.com</title> <description><![CDATA[<p align="left"><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - September 27, 2016) - </span>Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to announce that its Emesyl<sup>®</sup> anti-nausea homeopathic product is again available for purchase via Amazon.com.</p>]]></description> <pubDate>Tue, 27 Sep 2016 13:00 GMT</pubDate> <dc:identifier>1045204</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/20/1045201/0/en/Itonis-Inc-Signs-Facebook-Ad-Campaign-for-Its-Emesyl-Anti-Nausea-Homeopathic-Product-in-California-Market.html</guid> <link>https://www.globenewswire.com/news-release/2016/09/20/1045201/0/en/Itonis-Inc-Signs-Facebook-Ad-Campaign-for-Its-Emesyl-Anti-Nausea-Homeopathic-Product-in-California-Market.html</link> <title>Itonis, Inc. Signs Facebook Ad Campaign for Its Emesyl Anti-Nausea Homeopathic Product in California Market</title> <description><![CDATA[<p><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - September 20, 2016) - </span> Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to announce that it has signed an agreement with Facebook to run online advertisements over a 30-day period in its California Market for its Emesyl® anti-nausea Homeopathic product.</p>]]></description> <pubDate>Tue, 20 Sep 2016 14:00 GMT</pubDate> <dc:identifier>1045201</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/09/02/1045200/0/en/Itonis-Inc-to-Air-Emesyl-Commercial-Spots-in-the-Washington-DC-Market-for-Its-Emesyl-Anti-Nausea-Homeopathic-Product.html</guid> <link>https://www.globenewswire.com/news-release/2016/09/02/1045200/0/en/Itonis-Inc-to-Air-Emesyl-Commercial-Spots-in-the-Washington-DC-Market-for-Its-Emesyl-Anti-Nausea-Homeopathic-Product.html</link> <title>Itonis, Inc. to Air Emesyl Commercial Spots in the Washington, DC Market for Its Emesyl Anti-Nausea Homeopathic Product</title> <description><![CDATA[<p><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - September 02, 2016) - </span> Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></description> <pubDate>Fri, 02 Sep 2016 15:18 GMT</pubDate> <dc:identifier>1045200</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/07/21/1045199/0/en/Itonis-Inc-Announces-10-000-Commercial-Spots-for-Its-Emesyl-Anti-Nausea-Relief-Have-Begun.html</guid> <link>https://www.globenewswire.com/news-release/2016/07/21/1045199/0/en/Itonis-Inc-Announces-10-000-Commercial-Spots-for-Its-Emesyl-Anti-Nausea-Relief-Have-Begun.html</link> <title>Itonis, Inc. Announces 10,000 Commercial Spots for Its Emesyl Anti-Nausea Relief Have Begun</title> <description><![CDATA[<p><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - July 21, 2016) - </span> Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></description> <pubDate>Thu, 21 Jul 2016 14:09 GMT</pubDate> <dc:identifier>1045199</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="http://www.marketwire.com/library/MwGo/2016/7/21/11G107530/Images/Tier1-5d69dfd1735ba382be218bdedd205a5d.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2016/07/21/1045199/0/en/Itonis-Inc-Announces-10-000-Commercial-Spots-for-Its-Emesyl-Anti-Nausea-Relief-Have-Begun.html"> <img src="http://www.marketwire.com/library/MwGo/2016/7/21/11G107530/Images/Tier1-5d69dfd1735ba382be218bdedd205a5d.jpg" width="600" align="left" border="0" alt="Photo" title="The platform consists of 3 tiers on the following popular cable TV networks." /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <media:content medium="image" type="image/jpeg" width="600" url="http://www.marketwire.com/library/MwGo/2016/7/21/11G107530/Images/map-7d3aea1a7c27ad16a7e1bef32227e5b0.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2016/07/21/1045199/0/en/Itonis-Inc-Announces-10-000-Commercial-Spots-for-Its-Emesyl-Anti-Nausea-Relief-Have-Begun.html"> <img src="http://www.marketwire.com/library/MwGo/2016/7/21/11G107530/Images/map-7d3aea1a7c27ad16a7e1bef32227e5b0.jpg" width="600" align="left" border="0" alt="Photo" title="The following map shows where the ads are being aired within the states." /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/07/12/1045198/0/en/Itonis-Inc-Announces-the-Results-of-a-Case-Study-Testing-the-Effects-of-Its-Emesyl-Nasal-Relief-on-Severe-Nausea.html</guid> <link>https://www.globenewswire.com/news-release/2016/07/12/1045198/0/en/Itonis-Inc-Announces-the-Results-of-a-Case-Study-Testing-the-Effects-of-Its-Emesyl-Nasal-Relief-on-Severe-Nausea.html</link> <title>Itonis, Inc. Announces the Results of a Case Study Testing the Effects of Its Emesyl Nasal Relief on Severe Nausea</title> <description><![CDATA[<p><span class="mw_region">LAGUNA HILLS, CA</span><span>--(Marketwired - July 12, 2016) - </span>Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></description> <pubDate>Tue, 12 Jul 2016 13:30 GMT</pubDate> <dc:identifier>1045198</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/02/11/1045197/0/en/Itonis-Pharmaceutical-s-EMESYL-TM-Nausea-Relief-Convenience-Store-Test-Market-Begins-in-Lodi-California.html</guid> <link>https://www.globenewswire.com/news-release/2015/02/11/1045197/0/en/Itonis-Pharmaceutical-s-EMESYL-TM-Nausea-Relief-Convenience-Store-Test-Market-Begins-in-Lodi-California.html</link> <title>Itonis Pharmaceutical's EMESYL(TM) Nausea Relief Convenience Store Test Market Begins in Lodi, California </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Feb 11, 2015) - Itonis, Inc. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></description> <pubDate>Wed, 11 Feb 2015 18:43 GMT</pubDate> <dc:identifier>1045197</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/02/10/1045196/0/en/Itonis-Distribution-of-Its-EMESYL-TM-Nausea-Relief-Seeking-Marketing-Evaluation-to-Air-Infomercial-With-As-Seen-On-TV.html</guid> <link>https://www.globenewswire.com/news-release/2015/02/10/1045196/0/en/Itonis-Distribution-of-Its-EMESYL-TM-Nausea-Relief-Seeking-Marketing-Evaluation-to-Air-Infomercial-With-As-Seen-On-TV.html</link> <title>Itonis Distribution of Its EMESYL(TM) Nausea Relief Seeking Marketing Evaluation to Air Infomercial With "As Seen On TV" </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Feb 10, 2015) - Itonis (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased that its distributor (Hensley Brothers Distribution, LLC) has shipped Itonis' EMESYL™ Nausea Relief product to As Seen On TV Productions for efficacy and marketing evaluation. (<a rel="nofollow" href="http://www.accesswire.com/425615/Hensley-Brothers-Distribution-LLC-Ships-Itonis-Emesyl-Nausea-Relief-to-As-Seen-On-TV-Productions" title="">http://www.accesswire.com/425615/Hensley-Brothers-Distribution-LLC-Ships-Itonis-Emesyl-Nausea-Relief-to-As-Seen-On-TV-Productions</a>) </p>]]></description> <pubDate>Tue, 10 Feb 2015 14:00 GMT</pubDate> <dc:identifier>1045196</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/08/12/1045194/0/en/Itonis-Pharmaceuticals-Announces-First-Emesyl-R-Manufacturer-Production-Release-Date.html</guid> <link>https://www.globenewswire.com/news-release/2014/08/12/1045194/0/en/Itonis-Pharmaceuticals-Announces-First-Emesyl-R-Manufacturer-Production-Release-Date.html</link> <title>Itonis Pharmaceuticals Announces First Emesyl(R) Manufacturer Production Release Date </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Aug 12, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) </p>]]></description> <pubDate>Tue, 12 Aug 2014 12:30 GMT</pubDate> <dc:identifier>1045194</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/06/25/1045192/0/en/Itonis-Pharmaceuticals-Authorizes-Start-of-Emesyl-R-Inaugural-Production-Run.html</guid> <link>https://www.globenewswire.com/news-release/2014/06/25/1045192/0/en/Itonis-Pharmaceuticals-Authorizes-Start-of-Emesyl-R-Inaugural-Production-Run.html</link> <title>Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Jun 25, 2014) - <strong>Itonis, Inc. </strong>(<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) Itonis is pleased to announce that, with the finalization of its new packaging design and product labeling, it has given the go ahead to Oasis Health Products to produce 16,000 units of its Emesyl® homeopathic product. Itonis has pre-paid necessary funds to Oasis to commence the inaugural production run. </p>]]></description> <pubDate>Wed, 25 Jun 2014 12:00 GMT</pubDate> <dc:identifier>1045192</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/06/19/1045190/0/en/Itonis-Pharmaceuticals-Completes-Final-Package-Design-Enabling-Start-of-Emesyl-R-Production.html</guid> <link>https://www.globenewswire.com/news-release/2014/06/19/1045190/0/en/Itonis-Pharmaceuticals-Completes-Final-Package-Design-Enabling-Start-of-Emesyl-R-Production.html</link> <title>Itonis Pharmaceuticals Completes Final Package Design, Enabling Start of Emesyl(R) Production </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Jun 19, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to announce that the final product packaging and bottle label designs for its Emesyl® over-the-counter homeopathic product for nausea relief are now complete. The finalized packaging design includes the 800 product phone number, the product information website, the product UPC code, and a brand new visual look that is very appealing to consumers. New pictures of the final box and bottle designs can be found on the company's website news tab at # <a rel="nofollow" href="http://www.itonisholdings.com/news" title="">http://www.itonisholdings.com/news</a>. </p>]]></description> <pubDate>Thu, 19 Jun 2014 14:00 GMT</pubDate> <dc:identifier>1045190</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/06/02/1045189/0/en/Itonis-Pharmaceuticals-Receives-NDC-Number-From-FDA-to-Enable-Production-and-Marketing-of-Emesyl-R-Product.html</guid> <link>https://www.globenewswire.com/news-release/2014/06/02/1045189/0/en/Itonis-Pharmaceuticals-Receives-NDC-Number-From-FDA-to-Enable-Production-and-Marketing-of-Emesyl-R-Product.html</link> <title>Itonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Jun 2, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to announce that the U.S. Food & Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its Emesyl® over-the-counter homeopathic product for nausea relief. </p>]]></description> <pubDate>Mon, 02 Jun 2014 21:34 GMT</pubDate> <dc:identifier>1045189</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/05/08/1045185/0/en/Itonis-Inc-Signs-First-Retail-Merchant-for-MyECheck-s-Point-of-Sale-Mobile-Payment-Application.html</guid> <link>https://www.globenewswire.com/news-release/2014/05/08/1045185/0/en/Itonis-Inc-Signs-First-Retail-Merchant-for-MyECheck-s-Point-of-Sale-Mobile-Payment-Application.html</link> <title>Itonis, Inc. Signs First Retail Merchant for MyECheck's Point of Sale Mobile Payment Application </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - May 8, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced that it has signed a letter of intent with Valley Organics Inc. for retail use of MyECheck's patented mobile payment application that will facilitate point of purchase transactions for medical marijuana. </p>]]></description> <pubDate>Thu, 08 May 2014 13:30 GMT</pubDate> <dc:identifier>1045185</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/04/24/1045181/0/en/Itonis-Inc-Readies-Preliminary-Packaging-Design-for-Project-Cloud9-Cannabinoid-Based-Product.html</guid> <link>https://www.globenewswire.com/news-release/2014/04/24/1045181/0/en/Itonis-Inc-Readies-Preliminary-Packaging-Design-for-Project-Cloud9-Cannabinoid-Based-Product.html</link> <title>Itonis, Inc. Readies Preliminary Packaging Design for Project "Cloud9" Cannabinoid-Based Product </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 24, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today unveiled its preliminary packaging design for its cannabinoid-based product that had been code named Project "Cloud9." For an available image of the packaging design, please use this link: <a rel="nofollow" href="http://itonisholdings.com/wp-content/uploads/2014/04/Itonis_Cloud9_Package_IMG_2200-800x801.jpg" title="">http://itonisholdings.com/wp-content/uploads/2014/04/Itonis_Cloud9_Package_IMG_2200-800x801.jpg</a>.</p>]]></description> <pubDate>Thu, 24 Apr 2014 13:00 GMT</pubDate> <dc:identifier>1045181</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/04/22/1045178/0/en/Itonis-Pharmaceuticals-in-Final-Steps-of-NDC-Registration-With-FDA-for-Emesyl-Product.html</guid> <link>https://www.globenewswire.com/news-release/2014/04/22/1045178/0/en/Itonis-Pharmaceuticals-in-Final-Steps-of-NDC-Registration-With-FDA-for-Emesyl-Product.html</link> <title>Itonis Pharmaceuticals in Final Steps of NDC Registration With FDA for Emesyl Product </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 22, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) is pleased to share an update from its manufacturer that the Company's Emesyl™ anti-nausea product is in its final steps of completing the NDC registration with the Food and Drug Administration ("FDA"), and is being readied for the first production run. While the process has taken longer than expected, the Company is pleased with recent progress to deliver Emesyl™ to market. </p>]]></description> <pubDate>Tue, 22 Apr 2014 13:00 GMT</pubDate> <dc:identifier>1045178</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/04/16/1045174/0/en/Itonis-Inc-Signed-Exploratory-Analysis-Trial-for-Cloud9-Project-With-Valley-Organics-Inc.html</guid> <link>https://www.globenewswire.com/news-release/2014/04/16/1045174/0/en/Itonis-Inc-Signed-Exploratory-Analysis-Trial-for-Cloud9-Project-With-Valley-Organics-Inc.html</link> <title>Itonis, Inc. Signed Exploratory Analysis Trial for Cloud9 Project With Valley Organics Inc. </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 16, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced that it has signed an agreement with Valley Organics Inc. to start a 30-day "Exploratory Analysis Trial" for the Company's cannabinoid-based product that is presently named as its Cloud9 project.</p>]]></description> <pubDate>Wed, 16 Apr 2014 13:00 GMT</pubDate> <dc:identifier>1045174</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/04/08/1045170/0/en/Itonis-Inc-to-Profit-From-Transactional-Revenues-by-Marketing-Its-Licensed-MyECheck-Mobile-App-to-Marijuana-Dispensary-Market.html</guid> <link>https://www.globenewswire.com/news-release/2014/04/08/1045170/0/en/Itonis-Inc-to-Profit-From-Transactional-Revenues-by-Marketing-Its-Licensed-MyECheck-Mobile-App-to-Marijuana-Dispensary-Market.html</link> <title>Itonis, Inc. to Profit From Transactional Revenues by Marketing Its Licensed MyECheck Mobile App to Marijuana Dispensary Market </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 8, 2014) -  Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced its plans to market its MyECheck proprietary mobile app to the massively exploding marijuana dispensary market in order to facilitate cash-free point of sale transactions to gain transactional fee revenues. </p>]]></description> <pubDate>Tue, 08 Apr 2014 17:25 GMT</pubDate> <dc:identifier>1045170</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/04/03/1045167/0/en/Itonis-Inc-Developing-Cannabinoid-Based-Cloud9-Product.html</guid> <link>https://www.globenewswire.com/news-release/2014/04/03/1045167/0/en/Itonis-Inc-Developing-Cannabinoid-Based-Cloud9-Product.html</link> <title>Itonis, Inc. Developing Cannabinoid-Based "Cloud9" Product </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 3, 2014) -  Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced that it is in the final phase of its research and development of a cannabinoid-based product presently named "Cloud9™."</p>]]></description> <pubDate>Thu, 03 Apr 2014 13:30 GMT</pubDate> <dc:identifier>1045167</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/04/01/1045165/0/en/Itonis-Inc-Joins-the-National-Cannabis-Industry-Association-to-Advance-Into-the-Medical-Marijuana-Products-and-Services-Sector.html</guid> <link>https://www.globenewswire.com/news-release/2014/04/01/1045165/0/en/Itonis-Inc-Joins-the-National-Cannabis-Industry-Association-to-Advance-Into-the-Medical-Marijuana-Products-and-Services-Sector.html</link> <title>Itonis, Inc. Joins the National Cannabis Industry Association to Advance Into the Medical Marijuana Products and Services Sector </title> <description><![CDATA[<p>LAGUNA HILLS, CA--(Marketwired - Apr 1, 2014) - Itonis, Inc. (<exchange name="PINKSHEETS">PINKSHEETS</exchange>: <ticker name="ITNS">ITNS</ticker>) today announced that it has joined the National Cannabis Industry Association (NCIA) as a member in a part of the Company's preparations to expand into the medical marijuana products and services sector. The Company is positioning itself for tremendous opportunities in this vibrant sector in unison with its recent app licensing agreement with MyECheck, Inc.</p>]]></description> <pubDate>Tue, 01 Apr 2014 13:00 GMT</pubDate> <dc:identifier>1045165</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Itonis, Inc.</dc:contributor> <dc:modified>Thu, 21 Sep 2017 03:03 GMT</dc:modified> </item> </channel> </rss>